AEON Biopharma
AEON
81 hedge funds and large institutions have $226M invested in AEON Biopharma in 2022 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 3 reducing their positions, and 5 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 3
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
11% more funds holding
Funds holding: 73 → 81 (+8)
6% more capital invested
Capital invested by funds: $213M → $226M (+$13.4M)
4.99% more ownership
Funds ownership: 78.73% → 83.72% (+5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$4.55M |
| 2 |
Calamos Advisors
Naperville,
Illinois
|
+$2.46M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$1.81M |
| 4 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
+$955K |
| 5 |
MTCM
Mint Tower Capital Management
Amsterdam,
Netherlands
|
+$954K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$3.43M |
| 2 |
TCM
Tegean Capital Management
New York
|
-$491K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$470K |
| 4 |
Citigroup
New York
|
-$245K |
| 5 |
OCAM
Owl Creek Asset Management
New York
|
-$245K |
AEON Hedge Fund Activity: Q3 2022 in Review
81 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q3 2022, worth a combined $226M — up 6.3% from $213M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new AEON positions and 5 closed out — a net gain of 8 holders — while 18 added to existing stakes and 3 trimmed.
The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $4.55M. The largest seller was Picton Mahoney Asset Management, exiting entirely with an estimated $3.43M sold.
- 81 institutional investors held AEON Biopharma (AEON) as of Q3 2022, up from 73 in Q2 2022.
- Funds reported $226M of AEON Biopharma stock for Q3 2022, up 6.3% quarter-over-quarter.
- 13 funds opened new AEON Biopharma positions in Q3 2022 and 5 closed out, a net change of +8 holders.
- The largest AEON Biopharma buyer in Q3 2022 was BNP Paribas Financial Markets, an estimated $4.55M added.
- The largest AEON Biopharma seller in Q3 2022 was Picton Mahoney Asset Management, an estimated $3.43M sold.
Based on aggregated 13F filings for Q3 2022.